Skip to main content

Caliper Collaborates with DiscoveRx to Offer GPCR Assays on LabChip

NEW YORK (GenomeWeb News) – Caliper Life Sciences said today it has struck a collaboration agreement under which it will bundle its LabChip systems with DiscoveRx’s G-protein-coupled receptor assays for drug research. 
 
The Hopkinton, Mass.-based company said the combined offering includes DiscoveRx’s PathHunter Beta Arrestin and cAMP Hunter assays.
 
Caliper CEO Kevin Hrusovsky said in a statement that the collaboration will enable the company to expand its offerings to “provide researchers with the ability to prosecute GPCR targets in a functional cellular assay for lead optimization and profiling.”
 

Caliper’s entry into the GPCR drug discovery market is “an opportunity with substantial potential due to the importance of GPCR drugs and the number of active R&D programs in neuroscience, cardiovascular, inflammation and other disease areas,” Hrusovsky added.

 

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.